Research Analysts Offer Predictions for HIMS FY2024 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Seaport Res Ptn boosted their FY2024 earnings per share estimates for Hims & Hers Health in a research report issued on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will earn $0.25 per share for the year, up from their prior estimate of $0.23. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2025 earnings at $0.51 EPS.

HIMS has been the topic of several other reports. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Truist Financial upped their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. TD Cowen upped their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Piper Sandler restated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Hims & Hers Health Stock Up 0.9 %

HIMS stock opened at $23.62 on Thursday. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The stock has a market cap of $5.07 billion, a P/E ratio of 54.80 and a beta of 1.06. The business’s 50-day moving average price is $18.40 and its 200-day moving average price is $18.29.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company earned ($0.04) earnings per share. The firm’s revenue was up 77.1% on a year-over-year basis.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now directly owns 23,917 shares of the company’s stock, valued at $362,342.55. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock worth $15,987,230 in the last 90 days. 17.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quest Partners LLC raised its stake in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares during the period. Royce & Associates LP lifted its stake in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after buying an additional 49,500 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 164.9% during the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock worth $950,000 after purchasing an additional 32,108 shares during the last quarter. WealthPlan Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at about $1,042,000. Finally, Versor Investments LP purchased a new position in Hims & Hers Health in the third quarter worth approximately $634,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.